Search results
Lupin stock hits eight-year high at Rs 1,749 on healthy earnings outlook
Business Standard India· 3 days agoThe stock has nearly doubled in value over the last year and trades at consensus valuations of 33...
Sensex @80K: Power Grid to UltraTech Cement — 13 stocks outperformed Sensex in H12024; Check full...
Livemint· 3 days agoThe 30-share BSE Sensex is hovering above the Mount 80,000-mark, which the index first achieved on...
Bulls charge: Sensex closes above 80,000 mark as FII funds fuel market rally
Business Standard India· 3 days agoThis volatility can be partly attributed to the expiry of weekly index options on the NSE. However,...
Market extends record rally for 2nd day; VIX slides 2.65%
Business Standard India· 3 days agoAs per provisional closing data, the S&P BSE Sensex was up 62.87 points or 0.08% to 80,049.67. The...
Gainers & losers: Stocks and sectors that moved the most on July 4
CNBC Awaaz· 3 days agoIndian benchmark indices ended marginally higher in a volatile session on July 4. Top Nifty gainers...
Cipla vs Competitors: Analysing success behind Cipla's growth
Business Today· 3 days agoCompeting with giants like Sun Pharma and Dr. Reddy's Laboratories, Cipla's steadfast growth trajectory is reflected in metrics such as Cipla share ...
Lupin Shares Rise Over 6% After Kotak's Double Upgrade To 'Add'; Check Target Price - News18
News18· 3 days agoKIE’s bullishness over Lupin stems from the drugmaker’s strong US portfolio which makes it...
Porinju Veliyath-backed Kaya shares hit upper circuit; here's why
Business Today· 3 days agoShares of Kaya Ltd hit an upper circuit of 10 per cent to Rs 501.45 on Thursday, commanding a total...
Multibagger stock: Lupin shares rally after Kotak's double upgrade on pharma player
Business Today· 3 days agoShares of multibagger pharma stock Lupin Ltd surged during the trading session on Thursday after the...
Emcure Pharma IPO Day 2: Issue subscribed 2x; NIIs lead from the front
CNBC Awaaz· 3 days agoBrokerages have positively viewed Emcure Pharma's IPO, considering the public offer fairly priced...